| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/0091270012445206 |
| P698 | PubMed publication ID | 23436261 |
| P50 | author | Christine Garnett | Q41772806 |
| P2093 | author name string | Hong Zhao | |
| Jun Yang | |||
| Jeffery Summers | |||
| Atiqur Rahman | |||
| Jogarao V Gobburu | |||
| Yaning Wang | |||
| Patricia Keegan | |||
| William Pierce | |||
| Brian Booth | |||
| Genevieve Schechter | |||
| P433 | issue | 2 | |
| P921 | main subject | decision making | Q1331926 |
| P304 | page(s) | 160-166 | |
| P577 | publication date | 2013-01-24 | |
| P1433 | published in | The Journal of Clinical Pharmacology | Q7743562 |
| P1476 | title | The combination of exposure-response and case-control analyses in regulatory decision making | |
| P478 | volume | 53 |
| Q34051972 | A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer |
| Q49221285 | A retrospective examination of the US Food and Drug Administration's clinical pharmacology reviews of oncology biologics for potential use of therapeutic drug monitoring |
| Q26774752 | A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities |
| Q90203076 | Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting |
| Q92568703 | Application of Machine Learning in Drug Development and Regulation: Current Status and Future Potential |
| Q38969901 | Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis |
| Q36410210 | Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation |
| Q49383683 | Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology |
| Q96584350 | Characterizing exposure-response relationship for therapeutic monoclonal antibodies in immuno-oncology and beyond: challenges, perspectives and prospects |
| Q42372516 | Comparative assessment of clinical response in patients with rheumatoid arthritis between PF-05280586, a proposed rituximab biosimilar, and rituximab |
| Q38557331 | Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations |
| Q41819996 | Establishing Good Practices for Exposure-Response Analysis of Clinical Endpoints in Drug Development |
| Q38178093 | Evaluation of tumor size response metrics to predict survival in oncology clinical trials. |
| Q92439627 | Exposure-Response Analysis of Overall Survival for Tremelimumab in Unresectable Malignant Mesothelioma: The Confounding Effect of Disease Status |
| Q39061272 | Exposure-Response and Tumor Growth Inhibition Analyses of the Monovalent Anti-c-MET Antibody Onartuzumab (MetMAb) in the Second- and Third-Line Non-Small Cell Lung Cancer |
| Q54380348 | Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer. |
| Q58577360 | Exposure-response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma |
| Q38661133 | Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial |
| Q90242172 | HER2-targeted therapies - a role beyond breast cancer |
| Q30831967 | Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial |
| Q38351470 | Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities. |
| Q92310112 | Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome |
| Q47291273 | Population Pharmacokinetics of Durvalumab in Cancer Patients and Association with Longitudinal Biomarkers of Disease Status |
| Q34953673 | Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response |
| Q38666988 | Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens. |
| Q91338868 | Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial |
| Q86910705 | The right dose for every patient: a key step for precision medicine |
| Q38564877 | Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF-α experience to oncology |
| Q50606627 | Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response. |
| Q39090073 | Toward greater insights on pharmacokinetics and exposure-response relationships for therapeutic biologics in oncology drug development |
Search more.